PTC THERAPEUTICS, INC. — Director's Dealing 2021

Sep 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2021-09-02

Reporting Person: Boulding Mark Elliott (Exec. VP and CLO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-02	Common Stock	M	3363	$18.01	Acquired	51737	Direct
2021-09-02	Common Stock	S	3363	$45.012	Disposed	48374	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-02	Stock Option (Right to Buy)	$18.01	M	3363	Disposed	2028-01-02	Common Stock (3363)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right To Buy)	$218.4	2022-01-10	Common Stock (191.0)	191	Direct
Stock Option (Right To Buy)	$51.0	2025-01-01	Common Stock (85600.0)	85600	Direct
Stock Option (Right To Buy)	$30.86	2026-01-03	Common Stock (70000.0)	70000	Direct
Stock Option (Right to Buy)	$11.23	2027-01-02	Common Stock (4563)	4563	Direct
Stock Option (Right To Buy)	$33.02	2029-01-21	Common Stock (72500.0)	72500	Direct
Stock Option (Right To Buy)	$33.02	2029-01-21	Common Stock (17500.0)	17500	Direct
Stock Option (Right To Buy)	$51.16	2030-01-28	Common Stock (59500.0)	59500	Direct
Stock Option (Right to Buy)	$66.49	2031-01-05	Common Stock (59500)	59500	Direct

Footnotes

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021.

F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.00 to $45.04 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.

F4: Currently exercisable.

F5: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.

F6: This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.

F7: This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.

F8: This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.